|
業務類別
|
-- |
|
業務概覽
|
GNI Group Ltd is a clinical stage drug development company. It works on the treatment of diseases that are more common in Asia, especially Japan and China. It is engaged in the discovery, development, manufacture, and sale of drugs for thetreatment of cancer and inflammatory diseases. |
| 公司地址
| Shinjuku Park Tower, 3-7-1 Nishi-Shinjuku, Shinjuku-ku, Tokyo, JPN, 163-1030 |
| 電話號碼
| +81 353263097 |
| 傳真號碼
| +81 353263167 |
| 公司網頁
| http://www.gnipharma.com |
| 員工數量
| 349 |
| Dr. Ying Luo, PhD |
Director, President and Chief Executive Officer |
-- |
31/03/2025 |
| Mr. Ryosuke Matsui |
Director, Executive Vice President, Chief Operating Officer and Chief Financial Officer |
-- |
31/03/2025 |
|
|
| Mr. Thomas Eastling |
Director |
31/03/2025 |
| Mr. Hideaki Sashiwa |
Independent Director |
31/03/2025 |
| Ms. Kikuchi Kanako |
Independent Director |
31/03/2025 |
| Mr. Zhang Ping |
Director |
31/03/2025 |
| Dr. Ying Luo, PhD |
Director, President and Chief Executive Officer |
31/03/2025 |
| Mr. Masahiro Matsuoka |
Independent Director |
31/03/2025 |
| Mr. Ryosuke Matsui |
Director, Executive Vice President, Chief Operating Officer and Chief Financial Officer |
31/03/2025 |
|
|
|
|
